- Home
- MTAL vs APLT Comparison
MTAL vs APLT Comparison
Compare MTAL & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- APLT
- Stock Information
- Founded
- MTAL 2021
- APLT 2016
- Country
- MTAL Jersey
- APLT United States
- Employees
- MTAL N/A
- APLT N/A
- Industry
- MTAL Blank Checks
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- MTAL Finance
- APLT Health Care
- Exchange
- MTAL Nasdaq
- APLT Nasdaq
- Market Cap
- MTAL 994.0M
- APLT 52.9M
- IPO Year
- MTAL 2021
- APLT 2019
- Fundamental
- Price
- MTAL $12.03
- APLT $0.33
- Analyst Decision
- MTAL Hold
- APLT Buy
- Analyst Count
- MTAL 2
- APLT 7
- Target Price
- MTAL $12.63
- APLT $6.10
- AVG Volume (30 Days)
- MTAL 694.2K
- APLT 2.3M
- Earning Date
- MTAL 08-09-2025
- APLT 08-06-2025
- Dividend Yield
- MTAL N/A
- APLT N/A
- EPS Growth
- MTAL N/A
- APLT N/A
- EPS
- MTAL N/A
- APLT N/A
- Revenue
- MTAL $340,736,000.00
- APLT $265,000.00
- Revenue This Year
- MTAL $20.81
- APLT $1,768.13
- Revenue Next Year
- MTAL $21.10
- APLT $292.85
- P/E Ratio
- MTAL N/A
- APLT N/A
- Revenue Growth
- MTAL 114.30
- APLT N/A
- 52 Week Low
- MTAL $7.69
- APLT $0.30
- 52 Week High
- MTAL $14.93
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- MTAL 60.25
- APLT 46.71
- Support Level
- MTAL $11.94
- APLT $0.30
- Resistance Level
- MTAL $12.17
- APLT $0.36
- Average True Range (ATR)
- MTAL 0.11
- APLT 0.03
- MACD
- MTAL -0.09
- APLT 0.00
- Stochastic Oscillator
- MTAL 27.14
- APLT 46.22
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.